Search Results - "Rouquette, I."

Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer by Adam, J., Le Stang, N., Rouquette, I., Cazes, A., Badoual, C., Pinot-Roussel, H., Tixier, L., Danel, C., Damiola, F., Damotte, D., Penault-Llorca, F., Lantuéjoul, S.

“…Various programed death ligand 1 (PD-L1) immunohistochemistry (IHC) assays have been developed and used in clinical trials in association with different drugs…”
Get full text

Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network by Beau-Faller, M., Prim, N., Ruppert, A.-M., Nanni-Metéllus, I., Lacave, R., Lacroix, L., Escande, F., Lizard, S., Pretet, J.-L., Rouquette, I., de Crémoux, P., Solassol, J., de Fraipont, F., Bièche, I., Cayre, A., Favre-Guillevin, E., Tomasini, P., Wislez, M., Besse, B., Legrain, M., Voegeli, A.-C., Baudrin, L., Morin, F., Zalcman, G., Quoix, E., Blons, H., Cadranel, J.

“…There is scarce data available about epidermal growth factor receptor (EGFR) mutations other than common exon 19 deletions and exon 21 (L858R) mutations. EGFR…”
Get full text

Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program by Leduc, C., Merlio, J.P., Besse, B., Blons, H., Debieuvre, D., Bringuier, P.P., Monnet, I., Rouquette, I., Fraboulet-Moreau, S., Lemoine, A., Pouessel, D., Mosser, J., Vaylet, F., Langlais, A., Missy, P., Morin, F., Moro-Sibilot, D., Cadranel, J., Barlesi, F., Beau-Faller, M.

“…EGFR mutations cause inconsistent response to EGFR tyrosine-kinase inhibitors (TKI). To better understand these features, we reviewed all cases of EGFR-mutated…”
Get full text

High-throughput somatic mutation profiling in pulmonary sarcomatoid carcinomas using the LungCarta™ Panel: exploring therapeutic targets by Fallet, V., Saffroy, R., Girard, N., Mazieres, J., Lantuejoul, S., Vieira, T., Rouquette, I., Thivolet-Bejui, F., Ung, M., Poulot, V., Schlick, L., Moro-Sibilot, D., Antoine, M., Cadranel, J., Lemoine, A., Wislez, M.

“…Pulmonary sarcomatoid carcinomas (SC) are tumors characterized by poor prognosis and resistance to conventional platinum-based chemotherapy. This study sought…”
Get full text

New Insights on Diagnostic Reproducibility of Biphasic Mesotheliomas: A Multi-Institutional Evaluation by the International Mesothelioma Panel From the MESOPATH Reference Center by Galateau Salle, F, Le Stang, N, Nicholson, A G, Pissaloux, D, Churg, A, Klebe, S, Roggli, V L, Tazelaar, H D, Vignaud, J M, Attanoos, R, Beasley, M B, Begueret, H, Capron, F, Chirieac, L, Copin, M C, Dacic, S, Danel, C, Foulet-Roge, A, Gibbs, A, Giusiano-Courcambeck, S, Hiroshima, K, Hofman, V, Husain, A N, Kerr, K, Marchevsky, A, Nabeshima, K, Picquenot, J M, Rouquette, I, Sagan, C, Sauter, J L, Thivolet, F, Travis, W D, Tsao, M S, Weynand, B, Damiola, F, Scherpereel, A, Pairon, J C, Lantuejoul, S, Rusch, V, Girard, N

“…The 2015 WHO classification of tumors categorized malignant mesothelioma into epithelioid, biphasic (BMM), and sarcomatoid (SMM) for prognostic relevance and…”
Get more information

Immunohistochemistry to identify EGFR mutations or ALK rearrangements in patients with lung adenocarcinoma by Hofman, P., Ilie, M., Hofman, V., Roux, S., Valent, A., Bernheim, A., Alifano, M., Leroy-Ladurie, F., Vaylet, F., Rouquette, I., Validire, P., Beau-Faller, M., Lacroix, L., Soria, J.C., Fouret, P.

“…Immunohistochemistry has been proposed as a specific and sensitive method to identify EGFR mutations or ALK rearrangements in lung tumours. We assessed EGFR…”
Get full text

Sarcoid-like granulomatosis in cancer patients treated with immune checkpoints inhibitors by Faviez, G, Bousquet, E, Rabeau, A, Rouquette, I, Collot, S, Goumarre, C, Meyer, N, Prevot, G, Mazieres, J

“…Immune checkpoint inhibitors are becoming a standard treatment for many different cancers. Their toxicities are variable and include organ-specific dysimmune…”
Get more information

DNA replication stress response involving PLK1, CDC6, POLQ, RAD51 and CLASPIN upregulation prognoses the outcome of early/mid-stage non-small cell lung cancer patients by Allera-Moreau, C, Rouquette, I, Lepage, B, Oumouhou, N, Walschaerts, M, Leconte, E, Schilling, V, Gordien, K, Brouchet, L, Delisle, M B, Mazieres, J, Hoffmann, J S, Pasero, P, Cazaux, C

“…Lung cancer is the leading cause of cancer deaths worldwide. Clinical staging classification is generally insufficient to provide a reliable prognosis,…”
Get full text

Improvement of the cytological diagnostic accuracy of follicular thyroid lesions by the use of the Ki-67 proliferative index in addition to cytokeratin-19 and HBME-1 immunomarkers: a study of 61 cases of liquid-based FNA cytology with histological controls by Lacoste-Collin, L., d'Aure, D., Bérard, E., Rouquette, I., Delisle, M. B., Courtade-Saïdi, M.

“…Objectives To evaluate HBME‐1, cytokeratin‐19 (CK‐19) and Ki‐67 immunomarkers in order to increase the diagnostic accuracy of preoperative thyroid fine needle…”
Get full text

A comparison of low vs conventional‐dose heparin for minimal cardiopulmonary bypass in coronary artery bypass grafting surgery by Fromes, Y., Daghildjian, K., Caumartin, L., Fischer, M., Rouquette, I., Deleuze, P., Bical, O. M.

“…Summary The biocompatibility of minimal extracorporeal circuits has improved; however, anticoagulation is still required. We compared standard high‐dose…”
Get full text

Takotsubo cardiomyopathy and anaesthesia by Preti, A, Ceddaha, M, Christias, M, Scemama, M, Rouquette, I

Get full text

SP-0598: Cilengitide in continuous infusion with radio-chemotherapy in stage III NSCLC: A phase I clinical trial by Cohen-Jonathan Moyal, E, Massabeau, C, Filleron, T, Modesto, A, Bachaud, J.M, Rouquette, I, Dierickx, L, Aziza, R, Bigay-Game, L, Plat, G, Mounier, M, Gomez-Roca, C, Delord, J.P, Mazieres, J

Get full text

Interest of crizotinib in a lung cancer patient with de novo amplification of MET by Rabeau, A, Rouquette, I, Vantelon, J-M, Taranchon-Clermont, E, Mazières, J

“…Targeted therapy in lung cancer changes the prognostic and treatment of patients. MET is an oncogene including exon 14 mutations and gene amplification…”
Get more information

A brief overview of a lung cancer biomarker: thymidylate synthase by Rouquette, I, Mazieres, J

“…Thymidylate synthase (TS) is an enzyme, which catalyzes the methylation of deoxyuridylate to deoxythymidylate using 5.10-methylenetetrahydrofolate as a…”
Get more information

An unusual mediastinal mass by Bousquet, E, Pontier, S, Hermant, C, Rouquette, I, Meyer, N, Didier, A, Mazieres, J

“…Primary mediastinal tumors are rare diseases including a broad spectrum of pathologies ranging from the well-known, such as lymphoma, thymoma or germ-line…”
Get more information

SP-25: Continuous Infusion of Cilongitide with Radiochemotherapy in State III NSCL Carcinoma = A Phase 1 Study by Cohen-Jonathan Moyal, E, Massabeau, C, Filleron, T, Bachaud, J.M, Rouquette, I, Dierickx, L, Delord, J.P, Poublanc, M, Aziza, R, Mazieres, J

Get full text

The French mesothelioma network from 1998 to 2013 by Galateau-Sallé, Françoise, Gilg Soit Ilg, A, Le Stang, N, Brochard, P, Pairon, J C, Astoul, P, Frenay, C, Blaizot, G, Chamming's, S, Ducamp, S, Rousvoal, T, de Quillacq, A, Abonnet, V, Abdalsamad, I, Begueret, H, Brambilla, E, Capron, F, Copin, M C, Danel, C, de Lajartre, A Y, Foulet-Roge, A, Garbe, L, Groussard, O, Giusiano, S, Hofman, V, Lantuejoul, S, Piquenot, J M, Rouquette, I, Sagan, C, Thivolet-Bejui, F, Vignaud, J M, Scherpereel, A, Jaurand, M C, Jean, D, Hainaut, P, Chérié-Challine, L, Goldberg, M, Luce, D, Imbernon, E

“…Mesothelioma is a rare disease less than 0.3% of cancers in France, very aggressive and resistant to the majority of conventional therapies. Asbestos exposure…”
Get more information

Blood Vessel Invasion on Pre Treatment Biopsies Predicted Poor Prognosis in Patients with Advanced Non–small-cell Lung Carcinoma Treated with Radio and Chemotherapy by Massabeau, C, Filleron, T, Bachaud, J, Rouquette, I, Mazieres, J, Moyal, E

Get full text

Lung cancer in women and pregnancy: towards a hormonal origin? by Mazières, J, Rouquette, I, Brouchet, L

“…The incidence of lung cancer is increasing dramatically in women in France. It is now the leading cause of cancer deaths among women in the USA and the second…”
Get more information

Diagnostic value of bronchoscopy, CT and transbronchial biopsies in diffuse pulmonary lymphangiomatosis: case report and review of the literature by El Hajj, L., Mazières, J., Rouquette, I., Mittaine, M., Bolduc, J.P., Didier, A., Dahan, M., Joffre, F., Chabbert, V.C.

“…The authors present the case of a 48-year-old man with diffuse pulmonary lymphangiomatosis. This rare lymphatic disorder is characterized by proliferation of…”
Get full text